Skip to main content
. Author manuscript; available in PMC: 2019 Nov 6.
Published in final edited form as: ACS Pharmacol Transl Sci. 2018 Jul 25;1(1):50–60. doi: 10.1021/acsptsci.8b00003

Figure 3.

Figure 3.

SR9238 treatment significantly reduces lipogenesis and hepatic steatosis. RT-QPCR showing that SR9238 significantly suppresses genes encoding enzymes of the lipogenic pathway in the liver: (A) Fasn; (B) Srebp1c; (C) Srebf; (N = 10) as well as protein levels of (D) FASN and SREBP1 (N = 4). (Right panel) quantification of the Western blots shown in panels D: *p < 0.05 and * *p < 0.01.